|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
US4485045A
(en)
|
1981-07-06 |
1984-11-27 |
Research Corporation |
Synthetic phosphatidyl cholines useful in forming liposomes
|
|
US4544545A
(en)
|
1983-06-20 |
1985-10-01 |
Trustees University Of Massachusetts |
Liposomes containing modified cholesterol for organ targeting
|
|
US5444156A
(en)
|
1985-07-12 |
1995-08-22 |
Temple University-Of The Commonwealth System Of Higher Education |
Monoclonal antibodies to human plasma prekallikrein
|
|
US4777127A
(en)
|
1985-09-30 |
1988-10-11 |
Labsystems Oy |
Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
|
|
GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
|
WO1987005396A1
(en)
|
1986-03-03 |
1987-09-11 |
Brigham And Women's Hospital |
A method for evaluating nephrotoxicity
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US4704692A
(en)
|
1986-09-02 |
1987-11-03 |
Ladner Robert C |
Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
GB8702816D0
(en)
|
1987-02-07 |
1987-03-11 |
Al Sumidaie A M K |
Obtaining retrovirus-containing fraction
|
|
US5219740A
(en)
|
1987-02-13 |
1993-06-15 |
Fred Hutchinson Cancer Research Center |
Retroviral gene transfer into diploid fibroblasts for gene therapy
|
|
US5422120A
(en)
|
1988-05-30 |
1995-06-06 |
Depotech Corporation |
Heterovesicular liposomes
|
|
AP129A
(en)
|
1988-06-03 |
1991-04-17 |
Smithkline Biologicals S A |
Expression of retrovirus gag protein eukaryotic cells
|
|
US5045452A
(en)
|
1988-09-02 |
1991-09-03 |
Brigham And Women's Hospital |
Method for evaluating nephrotoxicity
|
|
EP0454781B1
(en)
|
1989-01-23 |
1998-12-16 |
Chiron Corporation |
Recombinant cells for therapies of infection and hyperproliferative disorders and preparation thereof
|
|
CA2425745C
(en)
|
1989-03-21 |
2005-03-29 |
Philip L. Felgner |
Expression of exogenous polynucleotide sequences in a vertebrate
|
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
|
WO1991002805A2
(en)
|
1989-08-18 |
1991-03-07 |
Viagene, Inc. |
Recombinant retroviruses delivering vector constructs to target cells
|
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
|
US5013556A
(en)
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
NZ237464A
(en)
|
1990-03-21 |
1995-02-24 |
Depotech Corp |
Liposomes with at least two separate chambers encapsulating two separate biologically active substances
|
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
|
ATE237694T1
(de)
|
1991-08-20 |
2003-05-15 |
Us Gov Health & Human Serv |
Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
|
|
ES2136092T3
(es)
|
1991-09-23 |
1999-11-16 |
Medical Res Council |
Procedimientos para la produccion de anticuerpos humanizados.
|
|
WO1993010218A1
(en)
|
1991-11-14 |
1993-05-27 |
The United States Government As Represented By The Secretary Of The Department Of Health And Human Services |
Vectors including foreign genes and negative selective markers
|
|
GB9125623D0
(en)
|
1991-12-02 |
1992-01-29 |
Dynal As |
Cell modification
|
|
FR2688514A1
(fr)
|
1992-03-16 |
1993-09-17 |
Centre Nat Rech Scient |
Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
|
|
US5733743A
(en)
|
1992-03-24 |
1998-03-31 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
|
EP0650370A4
(en)
|
1992-06-08 |
1995-11-22 |
Univ California |
METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
|
|
JPH09507741A
(ja)
|
1992-06-10 |
1997-08-12 |
アメリカ合衆国 |
ヒト血清による不活性化に耐性のあるベクター粒子
|
|
GB2269175A
(en)
|
1992-07-31 |
1994-02-02 |
Imperial College |
Retroviral vectors
|
|
EP0673431A1
(en)
|
1992-12-03 |
1995-09-27 |
Genzyme Corporation |
Gene therapy for cystic fibrosis
|
|
US5981568A
(en)
|
1993-01-28 |
1999-11-09 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
|
JP3545403B2
(ja)
|
1993-04-22 |
2004-07-21 |
スカイファルマ インコーポレイテッド |
医薬化合物を被包しているシクロデキストリンリポソーム及びその使用法
|
|
AU687829B2
(en)
|
1993-06-24 |
1998-03-05 |
Advec, Inc. |
Adenovirus vectors for gene therapy
|
|
ATE257176T1
(de)
|
1993-09-15 |
2004-01-15 |
Chiron Corp |
Rekombinanter alphavirus vektor
|
|
US6015686A
(en)
|
1993-09-15 |
2000-01-18 |
Chiron Viagene, Inc. |
Eukaryotic layered vector initiation systems
|
|
JP3875990B2
(ja)
|
1993-10-25 |
2007-01-31 |
カンジ，インコーポレイテッド |
組換えアデノウイルスベクターおよび使用方法
|
|
DK0729351T3
(da)
|
1993-11-16 |
2000-10-16 |
Skyepharma Inc |
Vesikler med reguleret afgivelse af aktivstoffer
|
|
US5795954A
(en)
|
1994-03-04 |
1998-08-18 |
Genentech, Inc. |
Factor VIIa inhibitors from Kunitz domain proteins
|
|
CA2158977A1
(en)
|
1994-05-09 |
1995-11-10 |
James G. Respess |
Retroviral vectors having a reduced recombination rate
|
|
WO1996017072A2
(en)
|
1994-11-30 |
1996-06-06 |
Chiron Viagene, Inc. |
Recombinant alphavirus vectors
|
|
US6265150B1
(en)
|
1995-06-07 |
2001-07-24 |
Becton Dickinson & Company |
Phage antibodies
|
|
AU2998597A
(en)
|
1996-05-06 |
1997-11-26 |
Chiron Corporation |
Crossless retroviral vectors
|
|
DE19632772A1
(de)
|
1996-08-14 |
1998-02-19 |
Basf Ag |
Neue Benzamidine
|
|
US5840871A
(en)
|
1997-01-29 |
1998-11-24 |
Incyte Pharmaceuticals, Inc. |
Prostate-associated kallikrein
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
EP1158997A2
(en)
|
1999-03-09 |
2001-12-05 |
University Of Southern California |
Method of promoting myocyte proliferation and myocardial tissue repair
|
|
IL161677A0
(en)
|
2001-11-08 |
2004-09-27 |
Protein Design Labs |
Stable liquid pharmaceutical formulation of igg antibodies
|
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
|
CN105001222B
(zh)
|
2002-08-21 |
2017-11-07 |
勃林格殷格翰制药两合公司 |
8‑[3‑氨基‑哌啶‑1‑基]‑黄嘌呤化合物，其制备方法及作为药物制剂的用途
|
|
UY28103A1
(es)
|
2002-12-03 |
2004-06-30 |
Boehringer Ingelheim Pharma |
Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos
|
|
EP1713929A2
(en)
|
2004-02-03 |
2006-10-25 |
Bayer HealthCare AG |
Diagnostics and therapeutics for diseases associated with plasma kallikrein (klkb1)
|
|
JP4733058B2
(ja)
|
2004-02-18 |
2011-07-27 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
８−［３−アミノ−ピペリジン−１−イル］−キサンチン、その製造及びそのｄｐｐ−ｉｖインヒビターの形態での使用
|
|
AU2005271523B2
(en)
|
2004-08-03 |
2011-09-15 |
Dyax Corp. |
hk1-binding proteins
|
|
DE102004044221A1
(de)
|
2004-09-14 |
2006-03-16 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
|
US7235530B2
(en)
|
2004-09-27 |
2007-06-26 |
Dyax Corporation |
Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
|
|
WO2007104541A2
(en)
|
2006-03-16 |
2007-09-20 |
Dyax Corp. |
Compositions and methods using serine protease inhibiting peptides for treating ophthalmic disorders
|
|
KR100846354B1
(ko)
*
|
2007-03-21 |
2008-07-15 |
(주) 프로탄바이오 |
혈청 당단백질부터 분리한 폐암 진단용 마커
|
|
JP2010536883A
(ja)
*
|
2007-08-23 |
2010-12-02 |
ジェンザイム・コーポレーション |
カリクレイン阻害剤を用いた治療
|
|
CN101928346B
(zh)
|
2009-07-31 |
2013-01-16 |
华中科技大学同济医学院附属同济医院 |
一种抗人组织激肽释放酶单克隆抗体及其制备
|
|
PL3459564T3
(pl)
|
2010-01-06 |
2022-04-19 |
Takeda Pharmaceutical Company Limited |
Białka wiążące kalikreinę osocza
|
|
KR102502293B1
(ko)
|
2011-01-06 |
2023-02-21 |
다케다 파머수티컬 컴패니 리미티드 |
혈장 칼리크레인 결합 단백질
|
|
WO2012142308A1
(en)
|
2011-04-13 |
2012-10-18 |
Activesite Pharmaceuticals, Inc. |
Prodrugs of inhibitors of plasma kallikrein
|
|
SMT201700515T1
(it)
|
2011-05-02 |
2018-01-11 |
Millennium Pharm Inc |
Formulazione per anticorpo anti- 4 7
|
|
US10316095B2
(en)
|
2012-02-16 |
2019-06-11 |
Santarus, Inc. |
Antibody formulations
|
|
US9216219B2
(en)
|
2012-06-12 |
2015-12-22 |
Novartis Ag |
Anti-BAFFR antibody formulation
|
|
CN111044725B
(zh)
|
2013-01-20 |
2024-03-29 |
武田药品工业株式会社 |
缓激肽介导的病症的评估和治疗
|
|
KR102658793B1
(ko)
|
2013-01-20 |
2024-04-19 |
다케다 파머수티컬 컴패니 리미티드 |
pKal 매개 장애의 평가, 검정 및 치료
|
|
EP3594244A1
(en)
|
2013-03-15 |
2020-01-15 |
Dyax Corp. |
Anti-plasma kallikrein antibodies
|
|
KR20140119396A
(ko)
|
2013-03-29 |
2014-10-10 |
삼성전자주식회사 |
단백질 약물의 액상 제형
|
|
KR20220107077A
(ko)
|
2014-01-21 |
2022-08-01 |
다케다 파머수티컬 컴패니 리미티드 |
혈장 칼리크레인 결합 단백질 및 유전성 혈관부종을 치료하는 데 있어서의 이의 용도
|
|
EP3122782A4
(en)
|
2014-03-27 |
2017-09-13 |
Dyax Corp. |
Compositions and methods for treatment of diabetic macular edema
|
|
MX2017012423A
(es)
|
2015-03-30 |
2018-01-26 |
Dyax Corp |
Inhibidores de calicreina plasmatica y uso de los mismos para prevenir el ataque del angioedema hereditario.
|
|
KR20250139401A
(ko)
|
2015-12-11 |
2025-09-23 |
다케다 파머수티컬 컴패니 리미티드 |
혈장 칼리크레인 저해제 및 유전성 혈관부종 발작을 치료하기 위한 이의 용도
|
|
WO2020047352A1
(en)
|
2018-08-30 |
2020-03-05 |
Dyax Corp. |
Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
|
|
TW202100561A
(zh)
|
2019-03-14 |
2021-01-01 |
美商戴氏公司 |
血漿胰舒血管素抑制劑及其於治療遺傳性血管水腫發作的用途
|